Article
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2016
Igawa Satoshi, Sato Yuichi, Ishihara Mikiko, Kasajima Masashi, Kusuhara Seiichiro, Nakahara Yoshiro, Otani Sakiko, Fukui Tomoya, Katagiri Masato, Sasaki Jiichiro, Masuda Noriyuki
Abstract excerpt
BACKGROUND: Pemetrexed monotherapy has come to be recognized as one of the standard secondline therapies for advanced nonsquamous nonsmall cell lung cancer (NSCLC). However, there have been no reports of studies that have evaluated the efficacy of pemetrexed according to type of active EGFR mutation, i.e., an exon 19 deletion or an L858R point mutation. MATERIALS AND METHODS: The records of nonsquamous NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.